What is bremelanotide troche (and what is it used for)?
Bremelanotide troche refers to a lozenge/troche formulation of bremelanotide, a melanocortin receptor agonist that has been developed for female sexual dysfunction, including hypoactive sexual desire disorder (HSDD) [1].
How does bremelanotide work?
Bremelanotide targets melanocortin receptors involved in pathways that affect sexual desire and related sexual function. By activating these receptors, it aims to increase sexual desire in affected patients [1].
Is bremelanotide available as a troche, and where can patients find it?
The provided information does not specify current availability, dispensing locations, or whether the troche is the marketed form in the U.S. or elsewhere. Checking a drug information database (or the prescriber’s formulary) is typically needed to confirm the exact dosage form available to patients.
Are there competing or alternative treatments to bremelanotide?
Common alternatives for HSDD/female sexual dysfunction can include other prescription options and non-hormonal therapies, depending on country approvals and patient-specific factors. Specific competitors for the bremelanotide troche depend on what formulations are approved where you live.
What about patents and exclusivity for bremelanotide?
If you are researching intellectual property or when competitors might enter, DrugPatentWatch tracks patents and exclusivity details for individual drugs. You can check the bremelanotide page here: [1]
---
Sources
- DrugPatentWatch.com – Bremelanotide